Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – Oppenheimer issued their Q1 2018 earnings per share estimates for shares of Neurocrine Biosciences in a research note issued to investors on Monday. Oppenheimer analyst J. Olson expects that the company will post earnings of ($0.16) per share for the quarter. Oppenheimer currently has a “Buy” rating and a $95.00 price objective on the stock. Oppenheimer also issued estimates for Neurocrine Biosciences’ Q2 2018 earnings at $0.02 EPS, Q3 2018 earnings at $0.26 EPS and FY2021 earnings at $7.36 EPS.
Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings data on Wednesday, November 1st. The company reported ($0.13) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.49) by $0.36. The business had revenue of $60.77 million for the quarter, compared to the consensus estimate of $29.38 million. During the same quarter last year, the firm earned ($0.43) EPS.
Neurocrine Biosciences (NBIX) traded down $0.21 during trading hours on Wednesday, hitting $75.88. The stock had a trading volume of 1,135,600 shares, compared to its average volume of 1,125,073. Neurocrine Biosciences has a fifty-two week low of $38.43 and a fifty-two week high of $83.84. The company has a debt-to-equity ratio of 1.05, a current ratio of 14.38 and a quick ratio of 14.37. The company has a market cap of $6,733.44, a PE ratio of -34.18 and a beta of 0.35.
A number of hedge funds have recently modified their holdings of the business. FMR LLC lifted its stake in Neurocrine Biosciences by 9.8% during the second quarter. FMR LLC now owns 13,211,023 shares of the company’s stock worth $607,707,000 after purchasing an additional 1,180,874 shares during the last quarter. Vanguard Group Inc. boosted its stake in Neurocrine Biosciences by 2.8% in the second quarter. Vanguard Group Inc. now owns 6,922,294 shares of the company’s stock valued at $318,426,000 after acquiring an additional 186,329 shares in the last quarter. Janus Henderson Group PLC lifted its stake in shares of Neurocrine Biosciences by 2.6% during the third quarter. Janus Henderson Group PLC now owns 5,507,763 shares of the company’s stock worth $337,516,000 after buying an additional 140,639 shares during the period. Perceptive Advisors LLC lifted its stake in shares of Neurocrine Biosciences by 33.9% during the third quarter. Perceptive Advisors LLC now owns 4,791,589 shares of the company’s stock worth $293,629,000 after buying an additional 1,214,000 shares during the period. Finally, BB Biotech AG lifted its stake in shares of Neurocrine Biosciences by 7.7% during the second quarter. BB Biotech AG now owns 3,446,552 shares of the company’s stock worth $158,541,000 after buying an additional 245,000 shares during the period.
In related news, insider Dimitri E. Grigoriadis sold 30,000 shares of Neurocrine Biosciences stock in a transaction on Wednesday, November 8th. The stock was sold at an average price of $74.58, for a total transaction of $2,237,400.00. Following the completion of the sale, the insider now owns 77,691 shares of the company’s stock, valued at $5,794,194.78. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Kyle Gano sold 24,818 shares of Neurocrine Biosciences stock in a transaction on Thursday, November 2nd. The shares were sold at an average price of $71.05, for a total value of $1,763,318.90. Following the sale, the insider now directly owns 84,596 shares of the company’s stock, valued at approximately $6,010,545.80. The disclosure for this sale can be found here. Insiders have sold 116,405 shares of company stock valued at $8,588,519 in the last three months. 4.80% of the stock is owned by corporate insiders.
WARNING: This story was originally published by Community Financial News and is owned by of Community Financial News. If you are accessing this story on another website, it was stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this story can be viewed at https://www.com-unik.info/2018/01/18/oppenheimer-weighs-in-on-neurocrine-biosciences-inc-s-q1-2018-earnings-nbix.html.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.